Introduction
and their role in the clinical behavior of breast cancer has been identified.
The immunohistochemical staining for steroid hormone receptors (estrogen and progesterone receptors, ER and PgR, respectively) and the human epidermal growth factor receptor-2 (HER2) helps to choose appropriate therapies and predict prognosis for breast cancer patients. For example, tamoxifen, a selective ER modulator, when used in patients with ER-positive breast cancer, leads to a better tumor response, longer survival, lower recurrence and reduced risk of death among patients with ER and/or PgR positive tumors than patients with ER and PgR negative tumors (Patil et al., 2011a) . Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 and other targeted therapies has shown success in the outcome of patients with early and metastatic breast cancer blocking downstream HER2 signaling to inhibit proliferation of tumor cells that overexpress HER2. However, it is not easily accessible to the patients due to its high cost and availability of generics has addressed this concern to some extent. Lack of expression of all three receptors (ER, PgR and HER2), the so called triple negative breast cancer (TNBC) is generally associated with poor prognosis (Basu et al., 2008) .
Some data on immunohistochemistry (IHC) of breast cancer among Indian women are now available (Munjal et al., 2009; Vaidyanathan et al., 2010; Ambroise et al., 2011; Patil et al., 2011a; Dogra et al., 2014) . However, HER2 staining for all newly diagnosed breast cancer patients is not a routine practice in many hospitals in India. Thus, data on all three IHC markers (ER, PgR and HER2) in Indian patients are scarce. Furthermore, previous published studies on IHC profile of breast cancer in Indian women had relatively small number of cases (Munjal et al., 2009; Vaidyanathan et al., 2010; Ambroise et al., 2011; Patil et al., 2011a) . The present analysis was conducted to assess the IHC profile of breast cancer patients in the Indian population and further correlate the IHC expression with various clinico-pathological characteristics at presentation.
Materials and Methods

Analysis participants
This is a retrospective analysis of women who presented with primary, unilateral breast cancer in the Department of Medical Oncology at Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India during the period from January 2008 to December 2011. Data was retrieved from the medical records of the hospital including both early and locally advanced cancer cases. Patients with metastatic breast cancer were excluded. Details of each patient related to the demographic profile, signs and symptoms, personal history, investigations, tumour profile, treatment and follow up were also recorded. The analysis was granted waiver by the Institutional Review Board of the Institute.
Immunohistochemistry
Tumor tissue samples (core biopsy/resection specimen) were fixed in 10% neutral buffered formalin for 12-24 hours. The appropriate sections of 1x1 cm with a 3 mm thickness were processed in an autoprocessor for 6-48 hours (for HER2) or 6-72 hours (for ER, PgR) as per College of American Pathologist (CAP) guidelines and embedded in paraffin wax. Around 4 µm thin sections were cut and spread onto the poly-L-lysine coated slides and dried overnight at room temperature. They were then deparaffinized using xylene and rehydrated with propanol.
Antigen retrieval for ER and PgR was done using TRIS EDTA buffer (pH9). The slide was immersed in a pressure cooker filled with heated TRIS EDTA buffer and brought to full pressure. Thereafter, the slide was cooled at room temperature, washed with tap water followed by washing in TRIS buffered saline (TBS). Then, the slide was dipped into 3% H 2 O 2 solution (50 ml Methanol + 1.5 ml H 2 O 2 ) for 10 minutes to block endogenous peroxidase activity followed by 3 washes in TBS. Each slide was covered with 100 µl 4% protein blocking reagent so as to block any non-specific antibodies. It was then incubated for one hour with 1:25 dilution of 100 µl mouse anti ER monoclonal primary antibody (clone EP1, DAKO) anti PgR monoclonal primary antibody (clone PgR 636, DAKO). After 3 washes in TBS, the slide was treated with 100 µl secondary antibody for 20 min. It was again given 3 washes in TBS followed by incubation with 100 µl polymer horse raddish peroxidase for 30 min at room temperature. The slide was again washed thrice in TBS. Thereafter, the slide was covered with freshly prepared DAB chromogen at room temperature for 10 minutes, washed in distilled water and counterstained with Gill's hematoxylin for 5 minutes. This was followed by dehydration with acetone and clearing by Xylene. The slide was then mounted with DPX, labelled and viewed under the microscope.
For HER2neu test, anti HER2neu primary antibody (HERCEPT, DAKO) was used. Antigen demasking was done by immersing the deparaffinized sections into pre heated citrate buffer (pH 6) in a coplin jar at a temperature of 90-950C in a water bath for 40 min. Pressure cooker is not preferred for antigen demasking of HER-2. The slides along with the buffer was then brought to room temperature, and subsequently washed with tap water followed by three washings in TBS. The slides were dipped in 3% H 2 O 2 solution for 10 minutes to block endogenous peroxidase activity. Slide was then immersed in 100 µl of 4% protein blocking reagent for 10 min at room temperature. This was followed by washing thrice in TBS and immersed in 100 µl primary antibody for 1 hour at room temperature. The slides were rinsed gently in TBS three times and immersed in visualizing agent for 30 min. Following this, the slide was incubated in 100 µl DAB for 10 min. It was washed with distilled water and counterstained with Gill's hematoxylin. This was followed by dehydration with acetone and clearing by Xylene. The :http://dx.doi.org/10.7314/APJCP.2015.16.12.4959 Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India slide was then mounted with DPX, labeled and viewed under the microscope.
The stained sections were examined for appropriateness of staining of slide controls, batch controls and internal controls. After accessing the control slides/ internal control, the immunoreactivity of the test sample was scored as per the ASCO-CAP guidelines (2007) of ER/ PgR ( Figure 1A and 1B) and HER2 ( Figure 1C ). Equivocal (HER2-2+) cases were tested for gene amplification by Fluorescent In-Situ Hybridization (FISH) as per FDA approved PATH VISION HER2 DNA Probe Kit II.
Statistical analysis
For continuous data, comparisons between groups were made using t-test. For categorical data, data analysis was conducted by using the Chi square test or Fisher's exact test as appropriate. Statistical analyses were conducted using GNU PSPP software (version 0.7.10). Statistical significance was evaluated at the 0.05 significance level for the two-sided tests.
Results
During the specified period of 4 years, a total of 1930 patients presented to the Medical Oncology Department with breast disease. Of these, a total of 646 patients were excluded from the analysis as shown in Figure 2 . The present analysis included 1,284 women with early and locally advanced breast carcinoma with complete data availability.
Mean age of patients was 52.1 years (range 25-93 years). Almost half (51.5%) of these patients were <50 years of age and 58.1% belonged to the post-menopausal group. A majority (82.1%) of women underwent modified radical mastectomy (MRM). Around 48.8% patients had right sided breast cancer.
The data on clinico-pathological features and receptor status are tabulated in Table 2 shows association of HER2 status with ER and PgR expression. Only 23.0% of women had HER2 positive status. HER2 overexpression was seen in 17.3% of the hormone positive tumors and 28.6% of hormone negative tumors and hence a statistically significant association of HER2 negative status with ER and/or PgR positive tumors was observed (p-value <0.0001).
A total of 306 (23.7%) patients were triple negative. The characteristics of TNBCs are highlighted in Table 3 . Patients with triple negative tumors presented at a mean age of 50 years and majority of the patients (51.5%) were in the age group of 20-50 years as compared to the non-triple negative tumor group (p-value 0.01). Triple negative tumors showed a strong statistical association with menopausal status (p-value <0.01), tumor grade (p-value <0.01), lymph node status (p-value <0.01), cancer stage (p-value <0.01), type of tumor (p-value <0.01), and ductal carcinoma in situ (p-value <0.01). Premenopausal women (51.5%), tumor grade 3 (73.1%), tumor size >20 mm (91.5%), negative lymph node status (58.7%), cancer stage II (72.5%) and invasive ductal carcinoma (98.4%) were more commonly observed among the patients with triple negative tumors.
Discussion
The present analysis assessed the relevance of IHC markers in relation to their clinico-pathological characteristics among 1,284 breast cancer patients in India. The analysis showed that 63.4% women were ER and/or PgR positive and only 23.1% women were HER2 positive. Overall, 23.7% women were triple negative and 10.0% tumors were both ER+/HER2 positive.
Hormone positivity is very important in determining the course of therapy as patients with positive hormonal status are suitable candidates for hormone therapy, given the higher numbers of low income strata, especially in developing countries like India (Manjunath et al., 2011) . PgR mirrors the functional estrogenic stimulus and is a significant prognostic and predictive factor of the ER status (Patil et al., 2011a) . We found 53.1% PgR positive and 62.1% ER positive women in this analysis, which is very similar to results reported by Ambroise et al (Ambroise et al., 2011) . Previous research suggests that about 45-65% Indian invasive breast cancer patients are positive for ER and/or PgR, and about 30-35% patients are negative for both ER and PgR (Ambroise et al., 2011; Patil et al., 2011a) . The proportion of ER/PgR negativity was 36.7% and ER and/or PgR positivity was 63.4% in the present analysis. The proportion of PgR positive but ER negative tumors was 1.2%, lower than that observed by Ambroise et al. (2011) and Patil et al. (2011a) , but comparable to the analysis by Shet et al. (2009) . This may be attributed to the clone which was being used for detecting progesterone receptor. Our analysis found a significant inverse association between HER2 expression and ER/PgR expression (p-value <0.0001), though the proportion of HER2 positive tumors expressing ER (43.3%) and PgR (31.9%) was substantially high. Our results are in conformity with previous reports that HER2 amplification or overexpression is generally present in 20 -30% of the breast cancer patients (Ambroise et al., 2011; Singhai et al., 2011) as 23.0% of our patients showed HER2 positivity. Our finding of 23.7% patients with triple negative status is similar to previous reports of 20-25% triple negative patients among Indian women with breast cancer (Ambroise et al., 2011; Patil et al., 2011b) . The triple negative tumors were commonly grade III tumors. This is in line with similar results from other studies in India (Ambroise et al., 2011; Patil et al., 2011b) .
Given the lack of awareness about screening, costs, fear and stigma associated with breast cancer in India, many women are diagnosed in later stages (Babu et al., 2013) . The prognosis depends up to a great extent on various factors including metastatic disease, tumor size and grade, hormone status and HER2 status. Younger age, higher histopathological grade are characteristics of TNBCs (Patil et al., 2011b) . Our analysis confirmed that triple negative women tended to be younger, premenopausal, and had higher proportions of infiltrating duct carcinomas with higher tumour grades, but negative lymph node status.
Detection of hormone receptor expression can guide the diagnosis and treatment for breast cancer (Zhang et al., 2013) . The response to therapy depends on the IHC profile of patients as reported by previous studies (Patil et al., 2011b) . Patients with ER positive breast tumors, those with ER negative but PgR positive status would be benefitted by tamoxifen; while those with HER2 positive tumors are resistant to tamoxifen (Group, 1998; Dowsett et al., 2006) . Further, HER2 positive tumors respond well to targeted therapy using transtuzumab, a humanized monoclonal antibody against HER2 (Romond et al., 2005; Perez et al., 2011) . The triple negative patients lack these receptors besides having larger tumor size and higher histologic grade. Thus, TNBCs patients may have relatively poorer prognosis as there are no effective systemic targeted therapies against them. We believe that a large cohort analysis would be required to assess predictive effect of these markers along with therapeutic options on the survival of breast cancer patients. Thus, comparative evaluation of the different therapeutic methods for treating TNBCs, would also be useful. The present analysis is an effort towards addressing these issues.
Our analysis also had few limitations. Inherent biases may be present due to the retrospective nature of the analysis. The database used for this analysis is not a population-based database. However, our hospital serves a large number of patients from the North Indian population and hence the results of the present analysis would be generalizable to Indian population. We could not include all patients registered in our database as shown in Figure 2 . Previous studies on IHC profile of breast cancer in Indian women have reported data on small number of patients. With detailed data availability for 1284 breast cancer patients, the present analysis is one of the largest studies from India.
In conclusion, our analysis, one of the largest studies from India, provides elaborate data on IHC profile of about 1300 breast cancer patients. Majority of the Indian breast cancer patients seen in our hospital presented with ER and PgR positive tumors. The triple negative patients tended to be younger, premenopausal, and were associated with higher tumor grades, negative lymph nodes status and lesser frequency of ductal carcinoma in situ. 
